Immunology & Inflammation
Immunology & Inflammation Pipeline
Building on its leadership in type 2 inflammation R&D, Sanofi is advancing against a range of immunological and inflammatory disorders, working across several core areas. It is pursuing several potential treatments, currently in clinical development, with an R&D pipeline that focuses on new approaches to addressing the underlying causes of these diseases.
Deepening Leadership in Type 2 inflammatory diseases
Inflammatory diseases such as asthma, atopic dermatitis (eczema), chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, and some environmental allergies are driven by excessive type 2 inflammation. Sanofi R&D teams are studying how to calm this response without compromising the body's ability to fight infection.
Sanofi continually generates new insights that could make a difference in the lives of patients with type 2 inflammatory diseases. For example, our collaboration with Regeneron centers on substances produced by white blood cells called interleukins, which can trigger a vicious cycle of inflammation and infection. In clinical studies, researchers are evaluating whether blocking two specific interleukins can potentially dial down inflammation and interrupt the cycle in many of these diseases.
With the addition of Principia Biopharma to the R&D community, Sanofi is also investigating other aspects of the type 2 pathway, such as mast cells (a type of white blood cell) and enzymes called tyrosine kinases. Using Tailored Covalency® technology, our teams are targeting these substances with the goal of restoring balance in the type 2 immune response and quality of life in patients.
